|
From: Argosy University University of Calgary University of Hawaii University of Manitoba University of Saskatchewan Alberta Children's Hospital Date: 2010 April Authors: Mehl-Madrona L, Leung B, Kennedy C, Paul S, Kaplan BJ. Journal: Journal of Child and Adolescent Psychopharmacology 20(2):95-103 Participants: 88 children Disorder: Autism Design: Matched groups • 44 children received EMPowerplus by parents’ choice • 44 similar children received conventional pharmaceutical treatment by parents’ choice Results: The EMPowerplus group had superior symptom improvement • lower activity level • less social withdrawal • less anger • less irritability • lower incidence of self-injurious behavior (SIB) • better spontaneity with the examiner • greater improvement on the Aberrant Behavior Checklist • greater improvement on the Clinical Global Impressions scale The EMPowerplus group had markedly fewer adverse events • less weight gain • greater improvement on the Clinical Global Impressions scale |